Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy ... the highest dose of amycretin ...

Dosing a statin (rosuvastatin ... and the Hartford Hospital Cholesterol Management Center. Approximately 2600 charts were reviewed to identify patients receiving rosuvastatin EOD who previously ...

Copyright 2025 The Associated Press. All Rights Reserved. A new poll from The Associated Press-NORC Center for Public Affairs Research looks at what U.S. adults think ...

From lens focal lengths and fill-flash to portraits, macro or stunning landscapes there are techniques for everyone. Learn how to use metering, considering composition and shoot everything from ...